Blog Introduction
If you've researched weight-loss medications recently, you've likely seen cagrilintide mentioned alongside semaglutide — sometimes as a rival, sometimes as a partner. The confusion is understandable: the two are often discussed together because they're frequently studied in combination, but they are not the same type of drug, and they are not at the same stage of approval.
Featured Products
This guide explains exactly how cagrilintide and semaglutide differ — mechanism, clinical trial results, side effects, and, importantly, where each one currently stands with the FDA — so you can understand the science accurately, whatever your reason for researching it.
Full Blog Content
Key Takeaways
- Semaglutide is a GLP-1 receptor agonist; cagrilintide is a long-acting amylin analog. They act on different receptors and different appetite-regulating pathways.
- Semaglutide is FDA-approved (Ozempic, Wegovy, Rybelsus). Cagrilintide is not yet FDA-approved, either alone or combined with semaglutide as CagriSema.
- In late-stage trials, the combination of cagrilintide and semaglutide (CagriSema) produced significantly more weight loss than semaglutide alone.
- Because cagrilintide has no FDA-approved product, there is currently no legitimate prescription pathway for it in the United States outside of clinical trials.
- Any cagrilintide product marketed for individual purchase or self-administration outside a clinical trial is not an approved medication and carries risks that a doctor cannot yet fully evaluate or monitor against an approved label.
What Is Semaglutide?
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics a gut hormone that increases insulin secretion, slows gastric emptying, and reduces appetite. It's FDA-approved under three brand names: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management.
What Is Cagrilintide?
Cagrilintide is a long-acting analog of amylin, a hormone naturally produced by the pancreas alongside insulin. Amylin helps regulate satiety, slows gastric emptying, and suppresses glucagon secretion — a different mechanism than GLP-1, even though the two pathways produce some overlapping effects on appetite.
Cagrilintide is being developed by Novo Nordisk, primarily in combination with semaglutide under the investigational name CagriSema. As of this writing, cagrilintide is not FDA-approved as a standalone medication or as part of CagriSema. Novo Nordisk filed a New Drug Application with the FDA in late 2025, with a decision expected in 2026.
Important: Because cagrilintide has no approved product on the U.S. market, there is no legitimate prescription pathway for it outside of enrollment in a clinical trial. Any product sold online as cagrilintide is not an FDA-approved medication.
Mechanism of Action: How They Differ
Feature | Semaglutide | Cagrilintide |
Drug class | GLP-1 receptor agonist | Amylin analog |
Hormone mimicked | GLP-1 (incretin) | Amylin |
Primary receptor | GLP-1 receptor | Amylin (calcitonin) receptor |
FDA approval status | Approved (Ozempic, Wegovy, Rybelsus) | Not approved; NDA under FDA review |
Typical use | Monotherapy for diabetes or weight loss | Studied mainly in combination with semaglutide |
Weight Loss Efficacy: What the Trials Show
Cagrilintide is rarely studied entirely on its own for long-term weight loss; most large trial data comes from CagriSema (cagrilintide plus semaglutide) compared against semaglutide alone or placebo.
Trial | Population | Result |
REDEFINE 1 (NEJM, phase 3) | Adults with overweight/obesity, no diabetes, 68 weeks | CagriSema: ~20.4% mean weight loss vs ~3.0% with placebo; separate analysis found ~22.7% with CagriSema vs ~16.1% with semaglutide alone and ~11.8% with cagrilintide alone |
REIMAGINE trials (NEJM/Lancet, phase 3) | Adults with type 2 diabetes | CagriSema produced significantly greater weight loss and more patients reaching 5%, 10%, 15%, and 20% weight-loss thresholds than placebo |
Multiple 2026 meta-analyses | Pooled RCT data, several thousand patients | CagriSema consistently outperformed semaglutide monotherapy on percentage weight loss and waist circumference reduction |
Featured Snippet Answer: Cagrilintide combined with semaglutide (CagriSema) produced greater weight loss than semaglutide alone in phase 3 trials — roughly 20–23% average body weight loss versus about 16% with semaglutide alone at 68 weeks. Cagrilintide is not yet FDA-approved on its own.
Side Effects: How Do They Compare?
Both drugs share a broadly similar side-effect profile, since amylin and GLP-1 pathways both affect digestion:
- Nausea
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- Injection-site reactions
- Fatigue
In trials, the combination (CagriSema) has shown a side-effect profile comparable to semaglutide alone, though gastrointestinal events and injection-site reactions were somewhat more frequent with the combination. Because cagrilintide is still investigational, its long-term safety profile as a standalone product is less established than semaglutide's, which has years of post-approval, real-world safety data.
Regulatory Status: A Critical Difference
This is the most important practical distinction between the two:
- Semaglutide: FDA-approved since 2017 (diabetes) and 2021 (weight management). Widely prescribed, dispensed through licensed pharmacies, with an established safety-monitoring track record.
- Cagrilintide: Not FDA-approved in any form as of this writing. Available only through clinical trials. An NDA for CagriSema was filed with the FDA in late 2025, with a regulatory decision expected sometime in 2026.
This means that, unlike the semaglutide-vs-tirzepatide comparison, this isn't a choice between two prescribable options — it's a comparison between an approved medication and an investigational one that isn't yet legally available by prescription in the U.S.
Common Mistakes People Make
- Assuming cagrilintide is simply “a stronger version” of semaglutide — it's a different hormone class, not a more potent GLP-1 drug.
- Assuming cagrilintide is currently available by prescription — it is not yet FDA-approved.
- Confusing CagriSema (the combination) with cagrilintide alone — most published efficacy data is for the combination, not cagrilintide by itself.
- Sourcing cagrilintide from online “research peptide” sellers for personal use — these products are not approved for human use and fall outside any medical monitoring framework.
What This Means for You
If you have obesity or a weight-related health condition and are exploring treatment options, semaglutide (Wegovy) is currently an FDA-approved option available by prescription today. Cagrilintide, and the CagriSema combination, may become available in the future pending FDA review — but as of now, the only way to access it is through enrollment in a clinical trial, which your doctor or an academic medical center can help you learn more about if you're interested.
A licensed healthcare provider can review your health history and help you understand which currently-approved options — semaglutide, tirzepatide, or others — are appropriate for you, and can keep you informed as cagrilintide's regulatory status develops.
Key Takeaways
- Semaglutide (GLP-1 agonist) and cagrilintide (amylin analog) work through different hormonal pathways.
- Semaglutide is FDA-approved; cagrilintide is not — it remains investigational, with an FDA decision on CagriSema expected in 2026.
- Combined cagrilintide-semaglutide (CagriSema) has outperformed semaglutide alone in phase 3 trials by a meaningful margin.
- Side-effect profiles are similar, though cagrilintide's long-term safety data is far less established than semaglutide's.
- There is currently no legitimate prescription pathway for cagrilintide in the U.S. outside of clinical trials.
Frequently Asked Questions
What is the difference between cagrilintide and semaglutide?
Semaglutide is a GLP-1 receptor agonist; cagrilintide is an amylin analog. They work on different hormone receptors, though both reduce appetite and slow gastric emptying. Semaglutide is FDA-approved; cagrilintide is not.
Is cagrilintide FDA-approved?
No. As of this writing, cagrilintide is not FDA-approved, either alone or in combination with semaglutide (CagriSema). An application is under FDA review, with a decision expected in 2026.
What is CagriSema?
CagriSema is the investigational combination of cagrilintide and semaglutide being developed by Novo Nordisk for weight management and type 2 diabetes.
Does cagrilintide work better than semaglutide for weight loss?
In phase 3 trials, the combination of cagrilintide and semaglutide (CagriSema) produced greater weight loss than semaglutide alone — roughly 20–23% versus about 16% average body weight loss at 68 weeks. Cagrilintide has not been extensively studied as a true standalone long-term therapy.
Can I buy cagrilintide right now?
Not as an approved medication. Cagrilintide is only available through enrollment in clinical trials. Products sold online as “research peptide” cagrilintide are not FDA-approved and are not intended for human use.
Is cagrilintide an amylin analog or a GLP-1 drug?
Cagrilintide is an amylin analog, not a GLP-1 drug. It's often studied alongside GLP-1 drugs like semaglutide because the two pathways produce complementary appetite-suppressing effects.
What are the side effects of cagrilintide?
In trials, cagrilintide and CagriSema produced side effects similar to semaglutide — mainly nausea, vomiting, diarrhea, and injection-site reactions — though GI events were somewhat more frequent with the combination therapy.
When will cagrilintide be available?
If the FDA approves CagriSema, it could become available following the agency's decision, expected sometime in 2026. Timing depends on the outcome of the regulatory review.
Is CagriSema the same as Wegovy?
No. Wegovy contains semaglutide only. CagriSema is a separate, investigational combination product containing both cagrilintide and semaglutide.
How does amylin affect weight loss?
Amylin is a hormone that increases feelings of fullness, slows gastric emptying, and suppresses glucagon secretion after meals — effects that complement, rather than duplicate, GLP-1 activity.
Can semaglutide and cagrilintide be taken together outside a clinical trial?
Not currently through a legitimate prescription pathway, since cagrilintide is not FDA-approved. Any combined use outside of an approved product or clinical trial would not be under standard medical monitoring.
Who is developing cagrilintide?
Cagrilintide is being developed by Novo Nordisk, the same company that makes semaglutide (Ozempic, Wegovy, Rybelsus).
What trials have studied cagrilintide?
Major trials include REDEFINE 1 (adults with obesity, published in NEJM) and the REIMAGINE trials (adults with type 2 diabetes), both evaluating CagriSema against semaglutide alone or placebo.
